Gosset Ownership
Public
Employees
~500
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Recursion Pharmaceuticals General Information
Recursion Pharmaceuticals has developed one of the largest integrated tech-biology platforms for industrialized drug discovery. The company leverages massive proprietary biological and chemical datasets with machine learning to identify novel therapeutics rapidly. Its lead asset for cerebral cavernous malformation has reached Phase II trials—one of the first AI-discovered drugs to do so—and it maintains a broad pipeline across rare disease and oncology. The company recently merged with Exscientia to further expand its AI capabilities and pipeline breadth.
Contact Information
Drug Pipeline
REC-617
Phase 1/2Key Partnerships
Roche & Genentech ($12B neuroscience partnership), Bayer ($50M investment + fibrosis/onco collaboration), Sanofi Genzyme, NVIDIA ($50M investment + cloud/A.I. collaboration)
Recursion Pharmaceuticals Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Feb 19, 2026 | $600.0K | Completed | Phase 2 |
To view Recursion Pharmaceuticals's complete valuation and funding history, request access »
Recursion Pharmaceuticals Financial Metrics
Market Cap
$1484.7M
Total Revenue
$6.5M
Enterprise Value
$902.6M